Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.

2024

Brain Commun. 2024 Nov 19;6(6):fcae414. doi: 10.1093/braincomms/fcae414. eCollection 2024.PMID: 39605973 Free PMC article.

Fernandes Gomes B, Kumar A, Ashton NJ, Hall S, Stomrud E, Smith R, Zetterberg H, Blennow K, Mattsson-Carlgren N, Hansson O.

Brain Commun. 2024 Nov 19;6(6):fcae414. doi: 10.1093/braincomms/fcae414. eCollection 2024.PMID: 39605973 Free PMC article.

2025 CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson’s disease
2025 Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease
2025 Plasma tau biomarkers for biological staging of Alzheimer’s disease
2025 Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer’s disease
2025 Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
2025 Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
2025 Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
2025 A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer’s disease
2025 The CentiMarker project: Standardizing quantitative Alzheimer’s disease fluid biomarkers for biologic interpretation.
2025 Characterizing visual read tau-PET-negative participants with Alzheimer’s disease dementia
2025 Associations between the EAT-Lancet planetary health diet and incident dementia.
2025 Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
2025 Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease.
2025 Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials